» Articles » PMID: 32459439

Executive Summary of the Early-Onset Breast Cancer Evidence Review Conference

Overview
Journal Obstet Gynecol
Date 2020 May 28
PMID 32459439
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The Centers for Disease Control and Prevention launched the Bring Your Brave campaign to increase knowledge about early-onset breast cancer, defined as breast cancer in women aged 18-45 years. The American College of Obstetricians and Gynecologists convened a panel of experts in breast disease from the Society for Academic Specialists in General Obstetrics and Gynecology to review relevant literature, validated tools, best practices, and practice guidelines as a first step toward developing educational materials for women's health care providers about early-onset breast cancer. Panel members conducted structured literature reviews, which were then reviewed by other panel members and discussed at an in-person meeting of stakeholder professional and patient advocacy organizations in April 2019. This article summarizes the relevant literature, existing guidance, and validated tools to guide health care providers in the prevention, early detection, and special considerations of early-onset breast cancer. Substantive knowledge gaps were noted and summarized to provide guidance for future research.

Citing Articles

Geographic differences in early-onset breast cancer incidence trends in the USA, 2001-2020, is it time for a geographic risk score?.

Kehm R, Daaboul J, Tehranifar P, Terry M Cancer Causes Control. 2025; .

PMID: 39937364 DOI: 10.1007/s10552-025-01968-7.


Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes.

Pareja F, Bhargava R, Borges V, Brogi E, Canas Marques R, Cardoso F NPJ Breast Cancer. 2025; 11(1):6.

PMID: 39856067 PMC: 11760369. DOI: 10.1038/s41523-025-00719-w.


Single-cell transcriptomics unveils multifaceted immune heterogeneity in early-onset versus late-onset cervical cancer.

Chen Q, Deng D, Zhu H, Li S World J Surg Oncol. 2025; 23(1):12.

PMID: 39810181 PMC: 11730844. DOI: 10.1186/s12957-025-03654-z.


Combining rare and common genetic variants improves population risk stratification for breast cancer.

Bolze A, Kiser D, Schiabor Barrett K, Elhanan G, Schnell Blitstein J, Neveux I Genet Med Open. 2024; 2:101826.

PMID: 39669587 PMC: 11613897. DOI: 10.1016/j.gimo.2024.101826.


Gremlin-2 is a novel tumor suppressor that negatively regulates ID1 in breast cancer.

Jung J, Kim N, Park J, Lim D, Kwon M, Gil W Breast Cancer Res. 2024; 26(1):174.

PMID: 39614338 PMC: 11606173. DOI: 10.1186/s13058-024-01935-1.


References
1.
Metcalfe K, Dennis C, Poll A, Armel S, Demsky R, Carlsson L . Effect of decision aid for breast cancer prevention on decisional conflict in women with a BRCA1 or BRCA2 mutation: a multisite, randomized, controlled trial. Genet Med. 2016; 19(3):330-336. DOI: 10.1038/gim.2016.108. View

2.
Scoccianti C, Lauby-Secretan B, Bello P, Chajes V, Romieu I . Female breast cancer and alcohol consumption: a review of the literature. Am J Prev Med. 2014; 46(3 Suppl 1):S16-25. DOI: 10.1016/j.amepre.2013.10.031. View

3.
Gnerlich J, Deshpande A, Jeffe D, Sweet A, White N, Margenthaler J . Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 2009; 208(3):341-7. PMC: 3262236. DOI: 10.1016/j.jamcollsurg.2008.12.001. View

4.
Parmigiani G, Chen S, Iversen Jr E, Friebel T, Finkelstein D, Anton-Culver H . Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med. 2007; 147(7):441-50. PMC: 2423214. DOI: 10.7326/0003-4819-147-7-200710020-00002. View

5.
Fu Y, Zhuang Z . Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis. Int J Clin Exp Pathol. 2014; 7(10):6419-29. PMC: 4230119. View